News
Immunyx selected as a Resident Quick Fire Challenge Partnering for Preparedness Recipient
June 2024
We are thrilled to be announced as one of the awardees for the #BLUEKNIGHT #QuickFireChallenge. Inspired to continue innovating for a better and safer future. Thank you to our project partners at Akagera Medicines, Inc and the great team at VLX Ventures who continues to support our vision.
Targeted nanoparticles modify neutrophil function in vivo
October 2022
Neutrophils play critical roles in a broad spectrum of clinical conditions. Accordingly, manipulation of neutrophil…
Immunyx selected as a Quick Fire Challenge Project Nextgen Recipient
September 2023
The Biomedical Advanced Research and Development Authority (BARDA) and Johnson & Johnson Innovation are thrilled to announce…
Immunyx selected as a BlueKnight Company
January 2023
Immunyx Pharma, a developer of immune modulating therapies for neutrophil based diseases, announced it has been selected…
